- Home
- ACOG vs FATE Comparison
ACOG vs FATE Comparison
Compare ACOG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- FATE
- Stock Information
- Founded
- ACOG 2000
- FATE 2007
- Country
- ACOG Canada
- FATE United States
- Employees
- ACOG N/A
- FATE N/A
- Industry
- ACOG
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACOG
- FATE Health Care
- Exchange
- ACOG Nasdaq
- FATE Nasdaq
- Market Cap
- ACOG 91.6M
- FATE 108.2M
- IPO Year
- ACOG N/A
- FATE 2013
- Fundamental
- Price
- ACOG $4.12
- FATE $1.11
- Analyst Decision
- ACOG Strong Buy
- FATE Hold
- Analyst Count
- ACOG 1
- FATE 8
- Target Price
- ACOG $20.00
- FATE $5.43
- AVG Volume (30 Days)
- ACOG 75.4K
- FATE 2.1M
- Earning Date
- ACOG 05-20-2025
- FATE 05-08-2025
- Dividend Yield
- ACOG N/A
- FATE N/A
- EPS Growth
- ACOG N/A
- FATE N/A
- EPS
- ACOG N/A
- FATE N/A
- Revenue
- ACOG N/A
- FATE $13,631,000.00
- Revenue This Year
- ACOG N/A
- FATE N/A
- Revenue Next Year
- ACOG N/A
- FATE N/A
- P/E Ratio
- ACOG N/A
- FATE N/A
- Revenue Growth
- ACOG N/A
- FATE N/A
- 52 Week Low
- ACOG $3.75
- FATE $0.66
- 52 Week High
- ACOG $7.00
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- ACOG N/A
- FATE 57.67
- Support Level
- ACOG N/A
- FATE $0.87
- Resistance Level
- ACOG N/A
- FATE $1.18
- Average True Range (ATR)
- ACOG 0.00
- FATE 0.14
- MACD
- ACOG 0.00
- FATE 0.04
- Stochastic Oscillator
- ACOG 0.00
- FATE 86.54
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.